LONDON (Thomson Financial) - ReNeuron Plc., a specialist medicines manufacturer, said it has received a U.S. patent grant notice for culturing and isolation of islet progenitor cells used in its ReN002 programme focused on a cell therapy treatment for Type 1 diabetes.
